Patents Assigned to Pfizer
  • Patent number: 6300363
    Abstract: This invention provides a compound of the following formula: and the pharmaceutically acceptable salts thereof, wherein L is oxygen or sulfur; Y is a direct bond or C1-4 alkylidene; Q is C1-6 alkyl, C3-7 cycloalkyl, phenyl, naphthyl, heteroaryl or the like; R1 is hydrogen, C1-6 alkyl or the like; R2 is hydrogen, C1-4 alkyl, C(O)R5 wherein R5 is C1-22 alkyl or C2-22 alkenyl, halosubstituted C1-8 alkyl, halosubstituted C2-8alkenyl, —Y—C3-7 cycloalkyl, —Y—C3-7 cycloalkenyl, phenyl, naphthyl, heteroaryl or the like; X is halo, C1-4 alkyl, hydroxy, C1-4 alkoxy or the like; and n is 0, 1, 2 or 3, with the proviso that a group of formula —Y—Q is not methyl or ethyl when X is hydrogen; L is oxygen; R1 is hydrogen; and R2 is acetyl. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.
    Type: Grant
    Filed: December 3, 1999
    Date of Patent: October 9, 2001
    Assignee: Pfizer Inc.
    Inventors: Rodney William Stevens, Kasumari Nakao, Kiyoshi Kawamura, Chikara Uchida, Shinya Fujiwara
  • Patent number: 6300335
    Abstract: 4-aminoquinazoline derivatives which are selective inhibitors of cGMP PDE are useful in the treatment of erectile dysfunction (impotence) in male animals, including man.
    Type: Grant
    Filed: May 22, 1997
    Date of Patent: October 9, 2001
    Assignee: Pfizer Inc.
    Inventors: Simon Fraser Campbell, Alexander Roderick Mackenzie, Anthony Wood
  • Patent number: 6300316
    Abstract: This invention relates to compounds of the formula and to pharmaceutically acceptable salts thereof. The compounds of formula 1 are potent antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1.
    Type: Grant
    Filed: August 23, 1999
    Date of Patent: October 9, 2001
    Assignee: Pfizer Inc
    Inventors: Katherine E. Brighty, Takushi Kaneko, Robert G. Linde, II, Hiroko Masamune, Paul R. McGuirk, Wei-Guo Su, Yong-Jin Wu, Bingwei V. Yang
  • Patent number: 6297380
    Abstract: This invention relates to a process for preparing compounds of the Formula I, wherein R1, R2 and Pt are as defined in the specification, which are intermediates in the synthesis of certain growth hormone secretagogue compounds. This invention further relates to processes for preparing the growth hormone secretagogues. The invention also relates to the compound of Formula I wherein R1 is H, R2 is 2,2,2-trifluoromethyl and Pt is Boc.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: October 2, 2001
    Assignee: Pfizer Inc.
    Inventors: Charles K. Chiu, David A. Griffith
  • Patent number: 6297269
    Abstract: Compounds of the formula I: and their compositions are useful as glycogen phosphorylase inhibitors.
    Type: Grant
    Filed: December 2, 1997
    Date of Patent: October 2, 2001
    Assignee: Pfizer Inc.
    Inventors: Bernard Hulin, Dennis J. Hoover, Judith L. Treadway, William H. Martin
  • Patent number: 6297382
    Abstract: A process is provided for preparing a compound of the formula: comprising deprotecting a compound of the formula
    Type: Grant
    Filed: July 20, 2000
    Date of Patent: October 2, 2001
    Assignee: Pfizer, Inc.
    Inventor: Robert W. Scott
  • Patent number: 6294538
    Abstract: This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, wherein R is as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith.
    Type: Grant
    Filed: March 29, 2000
    Date of Patent: September 25, 2001
    Assignee: Pfizer Inc.
    Inventor: Banavara L. Mylari
  • Patent number: 6294557
    Abstract: A compound of the following formula: and the salts thereof, wherein A is hydrogen, halo, hydroxy, or the like; the broken line represents an optional double bond with proviso that if the broken line is a double bond, then A is absent; Ar1 is optionally substituted phenyl or the like; Ar2 is aryl or heteroaryl selected from phenyl, napththyl, pyridyl, and the like, the aryl or heteroaryl being optionally substituted; R1 is hydrogen, hydroxy, C1-C4 alkyl, or the like; and R2 and R3 are independently selected from optionally substituted C1-C7 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, and the like or R2 and R3, together with the nitrogen atom to which they are attached, form an optionally substituted pyrrolidine, piperidine or morpholine ring. These compounds are useful as kappa agonists.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: September 25, 2001
    Assignee: Pfizer Inc.
    Inventors: Fumitaka Ito, Hiroshi Kondo
  • Patent number: 6294569
    Abstract: A compound of the following formula: and the salts thereof, wherein A is hydrogen, halo, hydroxy, or the like; the broken line represents an optional double bond with proviso that if the broken line is a double bond, then A is absent; Ar1 is optionally substituted phenyl or the like; Ar2 is aryl or heteroaryl selected from phenyl, napththyl, pyridyl, and the like, the aryl or heteroaryl being optionally substituted; R1 is hydrogen, hydroxy, C1-C4 alkyl, or the like; and R2 and R3 are independently selected from optionally substituted C1-C7 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, and the like or R2 and R3, together with the nitrogen atom to which they are attached, form an optionally substituted pyrrolidine, piperidine or morpholine ring. These compounds are useful as kappa agonists.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: September 25, 2001
    Assignee: Pfizer Inc.
    Inventors: Fumitaka Ito, Hiroshi Kondo
  • Patent number: 6294558
    Abstract: This invention provides a compound of the formula: or its pharmaceutically acceptable salt thereof, wherein A is partially unsaturated or unsaturated five membered heterocyclic, or partially unsaturated or unsaturated five membered carbocyclic, wherein the 4-(sulfonyl)phenyl and the 4-substituted phenyl in the formula (I) are attached to ring atoms of Ring A, which are adjacent to each other; R1 is optionally substituted aryl or heteroaryl, with the proviso that when A is pyrazole, R1 is heteroaryl; R2 is C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkylamino, C1-4 dialkylamino or amino; R3, R4 and R5 are independently hydrogen, halo, C1-4 alkyl, halo-substituted C1-4 alkyl or the like; or two of R3, R4 and R5 are taken together with atoms to which they are attached and form a 4-7 membered ring; R6 and R7 are independently hydrogen, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino or N,N-di C1-4 alkylamino; and m and n are independently 1, 2, 3 or
    Type: Grant
    Filed: December 15, 1999
    Date of Patent: September 25, 2001
    Assignee: Pfizer Inc.
    Inventors: Kazuo Ando, Tomoki Kato, Akiyoshi Kawai, Tomomi Nonomura
  • Patent number: 6294552
    Abstract: The present invention relates to compounds of formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11 are as defined herein. The above compounds of formula 1 are useful in the treatment of hyperproliferative disorders, such as cancer, in mammals. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering the compounds of formula 1 to a mammal requiring such treatment.
    Type: Grant
    Filed: July 27, 2000
    Date of Patent: September 25, 2001
    Assignee: Pfizer Inc.
    Inventors: Joseph P. Lyssikatos, Susan D. La Greca
  • Patent number: 6291489
    Abstract: This invention relates to processes for preparing compounds of the formula (I) and to processes for preparing certain intermediates of the formula wherein R1 is nitro, amino or protected amino; R2 is H, fluoro, chloro CF3, nitro, (C1-C4)alkyl, (C1-C4)alkoxy, amino or protected amino; and X1 is OH or a suitable leaving group, used in that process. The invention also relates novel to compounds of the formulae (II).
    Type: Grant
    Filed: May 5, 1999
    Date of Patent: September 18, 2001
    Assignee: Pfizer Inc.
    Inventors: Keith M DeVries, Robert L. Dow, Stephen W. Wright
  • Patent number: 6291656
    Abstract: The invention relates to compounds of the formula I and to pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I, methods of using said compounds of formula I in the treatment of infections, and methods of preparing said compounds of formula I.
    Type: Grant
    Filed: July 15, 1999
    Date of Patent: September 18, 2001
    Assignee: Pfizer Inc.
    Inventor: Yong-Jin Wu
  • Patent number: 6291520
    Abstract: Certain novel hydroxamic acid derivatives having the structure inhibit the enzyme lipoxygenase. These compounds, and the pharmaceutically acceptable salts thereof, are useful in the treatment or alleviation of inflammatory diseases, allergic conditions and cardiovascular diseases in mammals and as the active ingredient in pharmaceutical compositions for treating such conditions.
    Type: Grant
    Filed: June 28, 1993
    Date of Patent: September 18, 2001
    Assignee: Pfizer
    Inventors: Takafumi Ikeda, Akiyoshi Kawai, Takashi Mano, Yoshiyuki Okumura, Rodney William Stevens
  • Patent number: 6288246
    Abstract: The present invention relates to a process for preparing hydroxamic acids from hydroxylic acid intermediates wherein the carboxylic acid intermediate does not possess reactive substituents such as hydroxy or amino groups.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: September 11, 2001
    Assignee: Pfizer Inc
    Inventor: Joel M. Hawkins
  • Patent number: 6288225
    Abstract: Compounds of formula I are antagonists of Substance P and have activity against CNS and gastrointestinal disorders.
    Type: Grant
    Filed: June 28, 2000
    Date of Patent: September 11, 2001
    Assignee: Pfizer INC
    Inventors: Hiroaki Wakabayashi, Masaya Ikunaka
  • Patent number: 6288242
    Abstract: The invention relates to processes for preparing a compound of the formula and the enantiomer of said compound, wherein the benzoic acid moiety is attached at position 6 or 7 of the chroman ring, and R1, R2, and R3 are as defined herein. The invention further relates to intermediates that are useful in the preparation of the compound of formula X above.
    Type: Grant
    Filed: February 23, 2000
    Date of Patent: September 11, 2001
    Assignee: Pfizer Inc.
    Inventors: Anthony Piscopio, Joel M. Hawkins, Stephanie Caron, Sarah E. Kelly, Jeffrey W. Raggon, Michael J. Castaldi, Robert W. Dugger, Sally G. Ruggeri
  • Patent number: 6288120
    Abstract: Prostaglandin agonists of formula (I), in which, for example, A is a sulphonyl or acyl group, B is N or CH, M contains a ring and K and Q are linking groups, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits useful for the treatment of bone disorders including osteoporosis.
    Type: Grant
    Filed: June 11, 1999
    Date of Patent: September 11, 2001
    Assignee: Pfizer Inc.
    Inventors: Kimberly O. Cameron, Hua Z. Ke, Bruce A. Lefker, Robert L. Rosati, David D. Thompson
  • Patent number: 6284757
    Abstract: This invention relates to the use of compounds of formula I wherein R1, R2, R3, X, m and n are defined as in the specification, and their pharmaceutically acceptable salts, for the treatment of disorders of the serotonin system.
    Type: Grant
    Filed: August 11, 1999
    Date of Patent: September 4, 2001
    Assignee: Pfizer Inc.
    Inventor: Mark Allen Sanner
  • Patent number: 6284773
    Abstract: This invention is directed to pharmaceutical combination compositions and methods comprising (−)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof and PGE2 or a pharmaceutically acceptable salt thereof, methods of using such compositions and kits containing such compositions. The compositions are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass and frailty.
    Type: Grant
    Filed: July 14, 1999
    Date of Patent: September 4, 2001
    Assignee: Pfizer Inc.
    Inventors: HuaZhu Ke, David D. Thompson